Coexpression of Matrix Metalloproteinase-7 and Tissue Inhibitor of Metalloproteinase-1 as a Prognostic Biomarker in Gastric Cancer

Zhang, Yangyu; Qin, Linling; Ma, Xiaobo; Wang, Yueqi; Wu, Yanhua; Jiang, Jing

doi:10.1155/2020/8831466

Cited by 8 publications

(9 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, among the other pathways we found an increased expression of OLR1, that facilitates metastasis of gastric cancer through driving EMT and PI3K/AKT/GSK3β activation ( 108 ), and MMP7, identified as prognostic marker in gastric cancer when co-expressed with TIMP1 ( 98 ). Conversely HMGCS2, identified as tumor suppressor with prognostic impact in prostate cancer, resulted downregulated also in intestinal gastric cancer subset ( 109 ).…”

Section: Resultsmentioning

confidence: 93%

“…Among inflammatory pathways, we found also an overexpression of several genes identified as diagnostic or prognostic markers of gastric cancer including E2F1, that induces upregulation of lncRNA HCG18 thus stimulating proliferation and migration of gastric cancer ( 96 ), TIMP1, a key gene in the development of gastric cancer recognized as a potential prognostic marker when co-expressed with MMP-7 ( 97 , 98 ), S100A9, a diagnostic and prognostic biomarker in gastric cancer ( 99 , 100 ), and SERPINE1, highly expressed and significantly related to a poor prognosis of gastric adenocarcinoma ( 90 ). Interestingly, also LAMA5 that promotes colorectal liver metastasis growth, resulted upregulated in intestinal gastric cancer ( 101 ).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Analysis of Gastric Cancer Transcriptome Allows the Identification of Histotype Specific Molecular Signatures With Prognostic Potential

et al. 2021

View full text Add to dashboard Cite

Gastric cancer is the fifth most common malignancy but the third leading cause of cancer-associated mortality worldwide. Therapy for gastric cancer remain largely suboptimal making the identification of novel therapeutic targets an urgent medical need. In the present study we have carried out a high-throughput sequencing of transcriptome expression in patients with gastric cancers. Twenty-four patients, among a series of 53, who underwent an attempt of curative surgery for gastric cancers in a single center, were enrolled. Patients were sub-grouped according to their histopathology into diffuse and intestinal types, and the transcriptome of the two subgroups assessed by RNAseq analysis and compared to the normal gastric mucosa. The results of this investigation demonstrated that the two histopathology phenotypes express two different patterns of gene expression. A total of 2,064 transcripts were differentially expressed between neoplastic and non-neoplastic tissues: 772 were specific for the intestinal type and 407 for the diffuse type. Only 885 transcripts were simultaneously differentially expressed by both tumors. The per pathway analysis demonstrated an enrichment of extracellular matrix and immune dysfunction in the intestinal type including CXCR2, CXCR1, FPR2, CARD14, EFNA2, AQ9, TRIP13, KLK11 and GHRL. At the univariate analysis reduced levels AQP9 was found to be a negative predictor of 4 years survival. In the diffuse type low levels CXCR2 and high levels of CARD14 mRNA were negative predictors of 4 years survival. In summary, we have identified a group of genes differentially regulated in the intestinal and diffuse histotypes of gastric cancers with AQP9, CARD14 and CXCR2 impacting on patients’ prognosis, although CXCR2 is the only factor independently impacting overall survival.

show abstract

Section: Resultsmentioning

confidence: 93%

Section: Resultsmentioning

confidence: 99%

Analysis of Gastric Cancer Transcriptome Allows the Identification of Histotype Specific Molecular Signatures With Prognostic Potential

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Among inflammatory pathways, we found also an overexpression of several genes identified as diagnostic or prognostic markers of gastric cancer including E2F1, that induces upregulation of lncRNA HCG18 thus stimulating proliferation and migration of gastric cancer [96], TIMP1, a key gene in the development of gastric cancer recognized as a potential prognostic marker when coexpressed with MMP-7 [97,98], S100A9, a diagnostic and prognostic biomarker in gastric cancer [99,100], and SERPINE1, highly expressed and significantly related to a poor prognosis of gastric adenocarcinoma [90]. Interestingly, also LAMA5 that promotes colorectal liver metastasis growth, resulted upregulated in intestinal gastric cancer [101].…”

Section: Resultsmentioning

confidence: 99%

Analysis of gastric cancer transcriptome allows the identification of histotype specific molecular signatures with prognostic potential

Carino

Graziosi

Marchianò

et al. 2021

Preprint

View full text Add to dashboard Cite

Gastric cancer is the fifth most common malignancy but the third leading cause of cancer-associated mortality worldwide. Therapy for gastric cancer remain largely suboptimal making the identification of novel therapeutic targets an urgent medical need. In the present study we have carried out a high-throughput sequencing of transcriptome expression in patients with gastric cancers. Twenty-four patients, among a series of 53, who underwent an attempt of curative surgery for gastric cancers in a single center, were enrolled. Patients were sub-grouped according to their histopathology into diffuse and intestinal types, and the transcriptome of the two subgroups assessed by RNAseq analysis and compared to the normal gastric mucosa. The results of this investigation demonstrated that the two histopathology phenotypes express two different patterns of gene expression. A total of 2064 transcripts were differentially expressed between neoplastic and non neoplastic tissues: 772 were specific for the intestinal type and 407 for the diffuse type. Only 885 transcripts were simultaneously differentially expressed by both tumors. The per pathway analysis demonstrated an enrichment of extracellular matrix and immune dysfunction in the intestinal type including CXCR2, CXCR1, FPR2, CARD14, EFNA2, AQ9, TRIP13, KLK11 and GHRL. At the univariate analysis reduced levels AQP9 was found to be a negative predictor of 4 years survival. In the diffuse type low levels CXCR2 and high levels of CARD14 mRNA were negative predictors of 4 years survival. In summary, we have identified a group of genes differentially regulated in the intestinal and diffuse histo-types of gastric cancers with AQP9, CARD14 and CXCR2 impacting on patients prognosis, although CXCR2 is the only factor independently impacting overall survival.

show abstract

“…Cancer cells can synthesize MMPs and degrade ECM. By degrading ECM proteins and regulating the activity of other biomolecules, MMP7 is regarded as a central molecule associated with the stromal invasion of GC cells and PM formation [ 80 , 81 , 82 ].…”

Section: Multistep Processmentioning

confidence: 99%

Molecular Mechanisms and Potential Rationale of Immunotherapy in Peritoneal Metastasis of Advanced Gastric Cancer

Kang

Kim

2022

Biomedicines

View full text Add to dashboard Cite

Peritoneal metastasis (PM) is one of the most frequent metastasis patterns of gastric cancer (GC), and the prognosis of patients with PM is very dismal. According to Paget’s theory, disseminated free cancer cells are seeded and survive in the abdominal cavity, adhere to the peritoneum, invade the subperitoneal tissue, and proliferate through angiogenesis. In these sequential processes, several key molecules are involved. From a therapeutic point of view, immunotherapy with chemotherapy combination has become the standard of care for advanced GC. Several clinical trials of newer immunotherapy agents are ongoing. Understanding of the molecular process of PM and the potential rationale of immunotherapy for PM treatment is necessary. Beyond understanding of the molecular aspect of PM, many studies have been conducted on the modality of treatment of PM. Notably, intraperitoneal approaches, including chemotherapy or immunotherapy, have been conducted, because systemic treatment of PM has limitations. In this study, we reviewed the molecular mechanisms and immunologic aspects of PM, and intraperitoneal approaches under investigation for treating PM.

show abstract

Coexpression of Matrix Metalloproteinase-7 and Tissue Inhibitor of Metalloproteinase-1 as a Prognostic Biomarker in Gastric Cancer

Cited by 8 publications

References 54 publications

Analysis of Gastric Cancer Transcriptome Allows the Identification of Histotype Specific Molecular Signatures With Prognostic Potential

Analysis of Gastric Cancer Transcriptome Allows the Identification of Histotype Specific Molecular Signatures With Prognostic Potential

Analysis of gastric cancer transcriptome allows the identification of histotype specific molecular signatures with prognostic potential

Molecular Mechanisms and Potential Rationale of Immunotherapy in Peritoneal Metastasis of Advanced Gastric Cancer

Contact Info

Product

Resources

About